Acitretin (Neotigason®) - A review of pharmacokinetics and teratogenicity and hypothesis on metabolic pathways

M. L. Bouvy, M. C.J.M. Sturkenboom*, M. C. Cornel, L. T.W. De Jong-Van den Berg, B. H.C. Stricker, H. Wesseling

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Acitretin was introduced as a replacement for etretinate, the ethyl ester of acitretin. Acitretin is eliminated at a much faster rate than etretinate. Although both drugs are teratogens, the replacement was important especially as it allowed for a much shorter post-medication period in which pregnancy should be precluded. Recent findings showed the presence of etretinate in the plasma of acitretin-treated patients. This article gives a review of known metabolic pathways of the retinoids and tries to elucidate the possible conversion of acitretin into etretinate after acitretin ingestion.

Original languageEnglish
Pages (from-to)33-37
Number of pages5
JournalPharmaceutisch Weekblad Scientific Edition
Volume14
Issue number2
DOIs
Publication statusPublished - 1 Apr 1992
Externally publishedYes

Cite this